Global Dementia Associated with Alzheimer’s Disease Market is estimated to be valued at over USD 9.5 billion by 2033 and register a CAGR of over 4.6% during the forecast period 2025 to 2033.

Research has demonstrated that the aging population will not show signs of reduction, as there are disproportionate fertility rates and a rise in life expectancy. This fluctuation towards the aging population is projected to play a role in the high prevalence of Alzheimer’s disease, which, in turn, will cause a significant burden on health care systems, social care systems, and humans alike, on a global scale. Market study predicts that the surge in Alzheimer 's-related incidences is projected to augment the demand for improved therapies and innovative drugs.

Within the geriatric population, Alzheimer’s disease (AD) is a major cause of dementia. This, in turn, will lead to a significant degree of dependency on others in the later part of their lives. It is noteworthy that the available treatment can only provide relief from symptoms, but there is no known cure for the condition. The medication that is available cannot be easily acquired, and several patients are left with no choice but to suffer without any relief. Hence, there is a dire need for alternative treatments that is both innovative and effective. But fierce competition within the market for common drugs may hamper the global dementia associated with Alzheimer’s disease market growth.

Programs in AD drug development undergo stringent regulations and sanctions. If such a program needs to be conducted, it will have to undertake a period of 13 years, from the time of preclinical studies until the FDA sanctions it. Furthermore, the treatment for altering the effects of Alzheimer’s disease requires many strides and developments, but subsequently, it encounters many constraints. Such constraints range from insufficient surrogate markers, challenges in selecting ideal groups for clinical trials, as well as the sheer scale and length of time required to conduct such trials. Such factors can negatively affect the global dementia associated with Alzheimer’s disease market size

Among the foremost companies that undertake certain efforts and measures in formulating innovative drug programs is Ono Pharmaceutical Co., Ltd., a Japanese company. They have acquired further approval for the formulation, which contains new ingredients known as Exelon and Rivastigmine Patches. Both of these ingredients count as transdermal patches, which subdue the penetration of indications linked with mild to moderate dementia attributed to Alzheimer’s

Global Dementia Associated with Alzheimer’s Disease Market Segmentation:

By Drug Class

  • Cholinergic/ Cholinesterase (ChE) Inhibitors
    • Donepezil
    • Galantamine
    • Rivastigmine
  • Memantine
    • Combined Drug (Memantine
    • Donepezil) and Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail
  • Online Sales

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

While North America and Europe currently dominate the market, the Asia Pacific region is expected to witness accelerated growth. Factors contributing to this surge include a burgeoning elderly population, increased awareness of dementia-related conditions, and enhanced healthcare infrastructure. Countries like Japan, China, and India are at the forefront of this regional expansion.

Major players included in the Dementia Associated with Alzheimer's Disease Market:

  • Ono Pharmaceutical Co., Ltd.
  • Eisai Co., Ltd.
  • Johnson and Johnson Services, Inc.
  • Novartis AG
  • Allergan plc.
  • Merz Pharma GmbHCo. KGaA.
  • F. Hoffmann-La Roche Ltd
  • Daiichi Sankyo Company, Limited
  • Pfizer, Inc.
  • H. Lundbeck A/S.

Johnson & Johnson (J&J): In January 2025, J&J announced that its investigational therapies, Posdinemab and a tau-targeting active immunotherapy, received Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease. 

Novartis AG: Novartis continues to advance its neuroscience pipeline, focusing on innovative therapies for neurological conditions, including Alzheimer's disease. The company focuses on developing medicines that can significantly enhance treatment standards for patients worldwide.

Pfizer, Inc.: Although Pfizer has previously terminated its neuroscience discovery program, which included research into Alzheimer's disease treatment, the company continues to support dementia research through funding and collaborations. Pfizer is committing $150 million to fund new neuroscience research efforts outside their company, demonstrating a continued investment in the field.

Future Outlook: Emphasis on Early Diagnosis and Innovative Therapies

The market's future trajectory is expected to be influenced by advancements in early diagnostic tools and the development of disease-modifying treatments. Emerging technologies, including artificial intelligence and biomarker-based diagnostics, hold promise for earlier detection and intervention, potentially altering the disease course and improving patient outcomes.

Objectives of the Study:

  • To provide with an exhaustive analysis on the global dementia associated with Alzheimer’s disease market By Drug Class, By Distribution Channel, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Get unlimited analyst support and customise this study further to your requirements, contact sales@futurewiseresearch.com